

Financial news for DRNA dated on 2020-05-13: RBC Capital Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces Price Target of \$35

Financial news for DRNA dated on 2020-05-12: 78 Biggest Movers From Yesterday

Financial news for DRNA dated on 2020-05-11: SunTrust Robinson Humphrey Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to \$33

Financial news for DRNA dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for DRNA dated on 2020-05-07: Dicerna Pharmaceuticals Q1 EPS \$(0.310) May Not Compare To \$0.270 Estimate, Sales \$34.028M May Not Compare To \$59.830M Estimate

Financial news for DRNA dated on 2020-05-07: Dicerna Announces Appointment of Douglas Pagan as Chief Financial Officer

Financial news for DRNA dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for DRNA dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for DRNA dated on 2020-04-07: SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Raises Price Target to \$38

Financial news for DRNA dated on 2020-04-07: H.C. Wainwright Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to \$32

Financial news for DRNA dated on 2020-04-06: Alnylam and Dicerna Form a RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Financial news for DRNA dated on 2020-03-31: Dicerna Provides Initial Observations From PHYOX3 Trial Of Nedosiran For Treatment Of Primary Hyperoxaluria

Financial news for DRNA dated on 2020-03-26: Dicerna Pharma 8-K Shows Co. Plan To Address Business Continuity Amid Coronavirus Outbreak

Financial news for DRNA dated on 2020-03-19: Berenberg Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces \$35 Price Target

Financial news for DRNA dated on 2020-03-18: 7 Stocks Moving In Wednesday's After-Hours Session

Financial news for DRNA dated on 2020-03-18: Dicerna Receives Orphan Drug Designation From FDA For DCR-ALAT For Treatment Of Alpha-1 Antitrypsin Deficiency

Financial news for DRNA dated on 2020-02-28: Stifel Nicolaus Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to \$29

Financial news for DRNA dated on 2020-02-27: Dicerna Pharmaceuticals Q4 EPS \$(0.58) Does Not Compare To \$0.55 Estimate, Sales \$7.08M Does Not Compare To \$84.75M Estimate

Financial news for DRNA dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for DRNA dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for DRNA dated on 2020-01-09: B. Riley FBR Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to \$30

Financial news for DRNA dated on 2019-12-23: 60 Biggest Movers From Friday

Financial news for DRNA dated on 2019-12-20: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for DRNA dated on 2019-12-19: Dicerna Reports Closing Of Global Collab, Licensing Deal With Roche For Treatments For Chronic Hepatitis B Virus Infection

Financial news for DRNA dated on 2019-12-18: 10 Biggest Price Target Changes For Wednesday

Financial news for DRNA dated on 2019-12-18: Citigroup Maintains Buy on Dicerna

Pharmaceuticals, Raises Price Target to \$39

Financial news for DRNA dated on 2019-12-17: Dicerna Receives Orphan Drug Designation From European Commission For DCR-A1AT For Treatment Of Congenital Alpha-1 Antitrypsin Deficiency

Financial news for DRNA dated on 2019-12-13: Stocks That Hit 52-Week Highs On Friday

Financial news for DRNA dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for DRNA dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for DRNA dated on 2019-12-03: The Daily Biotech Pulse: Astellas To Buy Audentes For \$3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

Financial news for DRNA dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for DRNA dated on 2019-12-02: Stocks That Hit 52-Week Highs On Monday

Financial news for DRNA dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for DRNA dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for DRNA dated on 2019-11-25: 10 Biggest Price Target Changes For Monday

Financial news for DRNA dated on 2019-11-25: Baird Maintains Outperform on Dicerna Pharmaceuticals, Raises Price Target to \$50

Financial news for DRNA dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for DRNA dated on 2019-11-20: 77 Biggest Movers From Yesterday

Financial news for DRNA dated on 2019-11-19: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRNA dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for DRNA dated on 2019-11-19: H.C. Wainwright Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to \$30

Financial news for DRNA dated on 2019-11-19: 72 Biggest Movers From Yesterday

Financial news for DRNA dated on 2019-11-18: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for DRNA dated on 2019-11-18: Dicerna Pharmaceuticals shares are trading higher after the company entered into an agreement with Novo Nordisk to discover and develop RNAi Therapies for liver-related cardio-metabolic diseases.

Financial news for DRNA dated on 2019-11-18: Stocks That Hit 52-Week Highs On Monday

Financial news for DRNA dated on 2019-11-18: Mid-Morning Market Update: Markets Edge Lower; United Bankshares To Buy Carolina Financial

Financial news for DRNA dated on 2019-11-18: SunTrust Robinson Humphrey Assumes Dicerna Pharmaceuticals at Buy, Raises \$24 Price Target

Financial news for DRNA dated on 2019-11-18: Dicerna, Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Financial news for DRNA dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for DRNA dated on 2019-11-14: Stocks That Hit 52-Week Highs On Thursday

Financial news for DRNA dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for DRNA dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for DRNA dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for DRNA dated on 2019-11-07: Dicerna Pharmaceuticals Q3 EPS \$(0.45) Misses \$(0.28) Estimate, Sales \$8.035M Miss \$11.06M Estimate

Financial news for DRNA dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for DRNA dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for DRNA dated on 2019-10-31: 27 Stocks Moving In Thursday's Mid-Day Session

Financial news for DRNA dated on 2019-10-31: 15 Stocks Moving in Thursday's Pre-Market Session

Financial news for DRNA dated on 2019-10-31: Dicerna Enters Agreement With Roche To Develop And Commercialize DCR-HBVS For The Treatment Of Chronic Hepatitis B Virus (HBV) Infection; Co. To Receive \$200M Up Front Plus Up To \$1.47B In Milestone Payments

Financial news for DRNA dated on 2019-10-29: Benzinga's Top Upgrades, Downgrades For October 29, 2019

Financial news for DRNA dated on 2019-10-29: Baird Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces \$27 Price Target

Financial news for DRNA dated on 2019-10-28: Baird Initiates Coverage On Dicerna Pharmaceuticals With Outperform Rating And \$27 Price Target

Financial news for DRNA dated on 2019-08-08: Dicerna Pharmaceuticals Q2 EPS \$(0.35) Misses \$(0.31) Estimate, Sales \$5.7M Miss \$10.29M Estimate

Financial news for DRNA dated on 2019-07-15: Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1

Financial news for DRNA dated on 2019-07-02: Dicerna To Begin Clinical Development Of DCR-ALAT For Treatment Of Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Financial news for DRNA dated on 2019-06-21: Dicerna Highlights Presentation Of Additional Data From PHYOX1 Study Of DCR-PHXC In Patients With Primary Hyperoxaluria Type 1 And Type 2

Financial news for DRNA dated on 2019-05-29: 5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential

Financial news for DRNA dated on 2019-05-24: Benzinga's Top Upgrades, Downgrades For May 24, 2019

Financial news for DRNA dated on 2019-05-24: Citigroup Assumes Dicerna Pharmaceuticals, Inc. - Common Stock at Buy, Announces Price Target \$30

Financial news for DRNA dated on 2019-05-16: Dicerna Reports Dosing Of First Patient In Phase 1 Trial Of DCR-HBVS For Treatment Of Chronic Hep B Virus

Financial news for DRNA dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for DRNA dated on 2019-05-09: Dicerna Pharmaceuticals Q1 EPS \$(0.38) Misses \$(0.22) Estimate, Sales \$3.107M Miss \$10.3M Estimate

Financial news for DRNA dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for DRNA dated on 2019-05-02: Dicerna Submits Updated IND Application For DCR-PHXC For Treatment Of Primary Hyperoxaluria For The PHYOX2 Pivotal Trial

Financial news for DRNA dated on 2019-03-29: Dicerna Pharma Highlights Presentation Of Updated Data Showing Utility Of DCR-PHXC In Treating PH1, PH2

Financial news for DRNA dated on 2019-03-19: 36 Stocks Moving In Tuesday's Pre-Market Session

Financial news for DRNA dated on 2019-03-11: Dicerna Pharmaceuticals Q4 EPS \$(0.29) Misses \$(0.22) Estimate, Sales \$1.541M Miss \$7.78M Estimate

Financial news for DRNA dated on 2019-03-11: Earnings Scheduled For March 11, 2019

Financial news for DRNA dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for DRNA dated on 2019-02-26: Cowen & Co. Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating

Financial news for DRNA dated on 2019-01-28: Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus

Financial news for DRNA dated on 2019-01-04: UPDATE: Dicerna Will Be Eligible To Receive Up To \$170M In Potential Development, Commercial Milestones For Added Target

Financial news for DRNA dated on 2019-01-04: Dicerna Pharma Reports Received Added Target Deal With Boehringer Ingelheim For Upfront Payment Of \$5M

Financial news for DRNA dated on 2018-12-20: Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake

Financial news for DRNA dated on 2018-11-28: Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

Financial news for DRNA dated on 2018-11-28: Leerink Swann Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces \$24 Price Target

Financial news for DRNA dated on 2018-11-27: Leerink Initiates Coverage On Dicerna Pharma, Eidos Therapeutics, Intellia With Outperform Ratings, Alnylam, AvroBio, Ionis With Market Perform Ratings, REGENXBIO With Underperform

Financial news for DRNA dated on 2018-11-06: 7 Biggest Price Target Changes For Tuesday

Financial news for DRNA dated on 2018-11-06: Benzinga's Top Upgrades, Downgrades For November 6, 2018

Financial news for DRNA dated on 2018-11-06: A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings

Financial news for DRNA dated on 2018-11-06: B. Riley FBR Upgrades Dicerna Pharmaceuticals to Buy, Raises Price Target to \$21

Financial news for DRNA dated on 2018-11-06: B. Riley FBR Upgrades Dicerna Pharmaceuticals to Buy from Neutral; Raises Price Target to \$21 from \$13.50

Financial news for DRNA dated on 2018-11-05: Dicerna Pharmaceuticals Q3 EPS \$(0.35) Misses \$(0.25) Estimate, Sales \$1.545M Miss \$1.7M Estimate

Financial news for DRNA dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for DRNA dated on 2018-10-29: Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Oct. 29, 2018

Financial news for DRNA dated on 2018-10-29: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for DRNA dated on 2018-10-29: Hearing Unconfirmed Chatter Citi has Increased its Price Target on Dicerna Pharma to \$30

Financial news for DRNA dated on 2018-10-29: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Oct. 29, 2018

Financial news for DRNA dated on 2018-10-29: Mid-Morning Market Update: Markets Open Higher; IBM To Buy Red Hat In \$34B Deal

Financial news for DRNA dated on 2018-10-29: Dicerna Soars After Eli Lilly Invests \$100M In Licensing, Research Deal

Financial news for DRNA dated on 2018-10-29: Dicerna Pharmaceuticals shares are trading up 30.2% premarket after the company announced a licensing and research collaboration with Eli Lilly to develop and commercialize new medicines in cardio-metabolic disease, neurodegeneration and pain.

Financial news for DRNA dated on 2018-10-29: 30 Stocks Moving In Monday's Pre-Market

Session

Financial news for DRNA dated on 2018-10-29: Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain

Financial news for DRNA dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for DRNA dated on 2018-10-24: UPDATE: Dicerna To Receive \$22M Upfront Payment, \$15M Equity Investment And Potential For Added Milestone-Dependent, Royalty Payments

Financial news for DRNA dated on 2018-10-24: Alexion, Dicerna Report Collaboration To Discover, Develop RNAi Therapies For Complement-Mediated Diseases

Financial news for DRNA dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for DRNA dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for DRNA dated on 2018-09-14: 46 Biggest Movers From Yesterday

Financial news for DRNA dated on 2018-09-13: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for DRNA dated on 2018-09-13: Dicerna Pharmaceuticals shares are up 9.0% after Citigroup analysts earlier initiated coverage on the stock with a Buy Rating and \$27 price target.

Financial news for DRNA dated on 2018-09-13: Citigroup Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces \$27 Price Target

Financial news for DRNA dated on 2018-09-10: 52 Biggest Movers From Friday

Financial news for DRNA dated on 2018-09-07: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for DRNA dated on 2018-09-07: Mid-Day Market Update: Dow Falls 150 Points; Dicerna Pharmaceuticals Shares Spike Higher

Financial news for DRNA dated on 2018-09-07: Mid-Morning Market Update: Markets Mixed; Genesco Beats Q2 Views

Financial news for DRNA dated on 2018-09-07: The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

Financial news for DRNA dated on 2018-09-07: 55 Biggest Movers From Yesterday

Financial news for DRNA dated on 2018-09-07: Dicerna Prices 7.6M Share Follow-On Public Offering of Common Stock @\$13.02/Share

Financial news for DRNA dated on 2018-09-06: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for DRNA dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for DRNA dated on 2018-09-06: The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data

Financial news for DRNA dated on 2018-09-05: Dicerna Announces 6.15M Shares Common Stock Follow-On Offering

Financial news for DRNA dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for DRNA dated on 2018-09-05: Dicerna Announces Proof Of Concept For DCR-PHXC In The Treatment Of Primary Hyperoxaluria; Initial Six-Week Data Show Significant And Sustained Reduction In Urinary Oxalate Levels, Detailed Readout Expected In Q4

Financial news for DRNA dated on 2018-08-16: Stocks Which Set New 52-Week High Yesterday, August 15th

Financial news for DRNA dated on 2018-08-15: Benzinga's Top Upgrades, Downgrades For August 15, 2018

Financial news for DRNA dated on 2018-08-15: H.C. Wainwright Upgrades Dicerna Pharmaceuticals to Buy

Financial news for DRNA dated on 2018-08-08: Dicerna Says Has Sufficient Cash To Fund Current Operating Plan Through 2019

Financial news for DRNA dated on 2018-08-08: Dicerna Pharmaceuticals Q2 EPS \$(0.68) Misses \$(0.42) Estimate, Sales \$1.545M Miss \$1.78M Estimate

Financial news for DRNA dated on 2018-08-08: Earnings Outlook For Dicerna Pharmaceuticals

Financial news for DRNA dated on 2018-07-11: Dicerna Receives Recommendation From EMA Committee To Designate DCR-PHXC An Orphan Medicinal Product For Primary Hyperoxaluria In The EU

Financial news for DRNA dated on 2018-06-05: Jefferies Global Healthcare Begins Today, Presenters Include: Kadmon, Aeri Pharma, Chemed, Orthofix, Revance, Heron Therapeutics, and Dicerna Pharma

Financial news for DRNA dated on 2018-05-30: Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial, FDA Grants Orphan Drug Designation for DCR-PHXC for the Treatment of Primary Hyperoxaluria

Financial news for DRNA dated on 2018-05-17: Watching Dicerna Shares Amid Access Data Alert From FDA.gov Showing Orphan Drug Designation For Primary Hyperoxaluria Treatment

Financial news for DRNA dated on 2018-05-17: Dicerna Files For Mixed Shelf Offering Of Up To \$250M

Financial news for DRNA dated on 2018-05-14: Dicerna Says Believes Has Sufficient Cash To Fund Execution Of Current Plan Through '19

Financial news for DRNA dated on 2018-05-14: Dicerna Pharmaceuticals Q1 EPS \$(0.30) Beats \$(0.38) Estimate, Sales \$1.545M Miss \$1.87M Estimate

Financial news for DRNA dated on 2018-05-14: Earnings Scheduled For May 14, 2018

Financial news for DRNA dated on 2018-04-20: Dicerna Pharmaceuticals Shares Up 19.7% Following Settlement Of All Litigation With Alnylam

Financial news for DRNA dated on 2018-04-20: Hearing Evercore Raised Price Target On Dicerna From \$14 To \$17 On Settlement Announcement

Financial news for DRNA dated on 2018-04-20: UPDATE: Dicerna To Pay To Alnylam Upfront Fee Of \$2M Plus ~983K Shares Of DRNA; Will Also Pay Added \$13M Over Next 4 Years

Financial news for DRNA dated on 2018-04-20: Dicerna Pharma Reports Settlement Of All Litigation With Alnylam

Financial news for DRNA dated on 2018-04-20: Dicerna Option Alert: May 18 \$10 Calls at the Ask: 1000 @ \$1.801 vs 20 OI; Earnings 5/7 After Close [est] Ref=\$10.4019

Financial news for DRNA dated on 2018-03-29: 40 Biggest Movers From Yesterday

Financial news for DRNA dated on 2018-03-28: Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

Financial news for DRNA dated on 2018-03-28: Benzinga's Top Upgrades, Downgrades For March 28, 2018

Financial news for DRNA dated on 2018-03-28: B. Riley Initiates Coverage On Dicerna Pharmaceuticals with Neutral Rating, Announces \$10.00 Price Target

Financial news for DRNA dated on 2018-03-23: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for DRNA dated on 2018-03-23: Benzinga's Top Upgrades, Downgrades For March 23, 2018

Financial news for DRNA dated on 2018-03-23: H.C. Wainwright Downgrades Dicerna Pharmaceuticals to Neutral

Financial news for DRNA dated on 2018-03-22: 21 Stocks Moving In Thursday's Pre-Market Session

Financial news for DRNA dated on 2018-03-21: 33 Biggest Movers From Yesterday

Financial news for DRNA dated on 2018-03-20: 28 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRNA dated on 2018-03-09: Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point

Financial news for DRNA dated on 2018-03-08: Dicerna Pharma Says It Believes Co. Has Sufficient Cash To Fund Operations Through 2019

Financial news for DRNA dated on 2018-03-08: Dicerna Pharma Reports Q4 EPS \$(0.90) vs \$(0.77) Est., Sales \$1.418M vs \$1.36M Est.

Financial news for DRNA dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for DRNA dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for DRNA dated on 2018-02-05: Benzinga's Top Upgrades, Downgrades For February 5, 2018

Financial news for DRNA dated on 2018-02-05: SunTrust Robinson Humphrey Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces \$13.00 Price Target

Financial news for DRNA dated on 2018-01-24: 40 Biggest Movers From Yesterday

Financial news for DRNA dated on 2018-01-23: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for DRNA dated on 2018-01-16: Evercore ISI Group Initiates Coverage On Dicerna Pharmaceuticals with Outperform Rating, Announces \$14.00 Price Target

Financial news for DRNA dated on 2018-01-10: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for DRNA dated on 2017-12-20: Dicerna Pharma Amended 13D Filing From RA Capital Shows Raised Stake From ~2.4M Shares As Of End Of Last Qtr. To ~5.07M Shares, Or 9.9% Stake

Financial news for DRNA dated on 2017-12-19: 13D/A Filing Shows Bain Capital Life Sciences Fund Reporting 15.7% Stake In Dicerna Pharmaceuticals

Financial news for DRNA dated on 2017-12-14: Dicerna Shares Down 9% Following Pricing Of ~5.71M Share Offering at \$7/Share

Financial news for DRNA dated on 2017-12-14: Dicerna Prices Offering Of ~5.71M Shares At \$7/Share

Financial news for DRNA dated on 2017-12-13: Dicerna Reports Offering Of Common Stock, No Amount Disclosed

Financial news for DRNA dated on 2017-12-07: Dicerna Pharma Announces 1st Human Dosed In Phase 1 Trial Of DCR-PHXC

Financial news for DRNA dated on 2017-11-20: StreetSweeper Issues New Short Report On Dicerna Pharmaceuticals

Financial news for DRNA dated on 2017-11-16: 40 Biggest Movers From Yesterday

Financial news for DRNA dated on 2017-11-15: Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics

Financial news for DRNA dated on 2017-11-03: 66 Biggest Movers From Yesterday

Financial news for DRNA dated on 2017-11-02: Dicerna Reports Q3 EPS \$(0.92) vs \$(0.69) Est., Sales \$474K vs \$20K Est.

Financial news for DRNA dated on 2017-11-02: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for DRNA dated on 2017-11-02: Dicerna Option Alert: Jan 19 \$7.5 Calls at the Ask: 1000 @ \$0.7 vs 22 OI; Ref=\$7.5

Financial news for DRNA dated on 2017-11-02: Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis

Financial news for DRNA dated on 2017-11-02: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for DRNA dated on 2017-10-16: Dicerna Pharma Files Clinical Trial Application for DCR-PHXC

Financial news for DRNA dated on 2017-10-10: Mid-Afternoon Market Update: KalVista Surges On Collaboration Deal With Merck; Izea Shares Plunge

Financial news for DRNA dated on 2017-10-10: 12 Biggest Mid-Day Losers For Tuesday

Financial news for DRNA dated on 2017-08-10: Dicerna Reports Q2 Loss/Share \$(1.15) vs. \$(0.60) Est., Sales \$252K vs. \$20K Est.

Financial news for DRNA dated on 2017-05-08: Dicerna Pharmaceuticals Reports Q1 EPS \$(0.68) vs \$(0.70) Est., Sales \$133K vs \$20K Est.

Financial news for DRNA dated on 2017-04-20: Domain Partners VIII Reports 14.9% Stake In Dicerna Pharmaceuticals

Financial news for DRNA dated on 2017-04-16: What Success Is Made Of: Investors, Execs And Entrepreneurs Talk About Their Routines And Role Models - Part 2

Financial news for DRNA dated on 2017-04-10: What Success Is Made Of: Investors, Execs And Entrepreneurs Talk Routines And Role Models

Financial news for DRNA dated on 2017-04-03: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for DRNA dated on 2017-03-31: 15 Biggest Mid-Day Gainers For Friday

Financial news for DRNA dated on 2017-03-30: Dicerna Says Expects to Have Sufficient Cash to Fund the Execution of Co.'s Current Operations Into 2019

Financial news for DRNA dated on 2017-03-30: Dicerna Pharma Reports Q4 Loss \$14M, \$(0.68) vs \$(0.73) Est., Sales \$133K

Financial news for DRNA dated on 2017-03-30: Earnings Scheduled For March 30, 2017

Financial news for DRNA dated on 2017-03-10: How The Ultra-Wealthy Are Helping Advance Health And Life Sciences

Financial news for DRNA dated on 2017-03-08: Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gutermann

Financial news for DRNA dated on 2017-03-03: Family Office Legend Thomas Gutermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused On Pre-IPO Unicorns'

Financial news for DRNA dated on 2017-02-22: Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump

Financial news for DRNA dated on 2017-02-16: Exclusive: Dicerna CEO Discusses Financials And Institutional Investors

Financial news for DRNA dated on 2017-02-15: Exclusive: Dicerna CEO Talks Products, Partnerships And Stock Performance

Financial news for DRNA dated on 2017-02-14: Exclusive: Dicerna CEO Explains RNA Interference And How It's Used To Treat Rare Genetic Diseases

Financial news for DRNA dated on 2017-01-31: Leerink Swann Initiates Coverage On Dicerna Pharmaceuticals To Market Perform

Financial news for DRNA dated on 2016-12-12: Benzinga's Top Initiations

Financial news for DRNA dated on 2016-12-12: H.C. Wainwright Initiates Coverage On Dicerna Pharmaceuticals at Buy, Announces \$7.00 Target

Financial news for DRNA dated on 2016-11-16: Dicerna Pharmaceuticals Inc: FAMBROUGH DOUGLAS (Director,Chief Executive Officer) Buys 33,100 @ Avg Price: \$3.71 (Form4)

Financial news for DRNA dated on 2016-11-09: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for DRNA dated on 2016-11-07: Dicerna Pharma Reports Q3 Net Loss \$14.2M vs \$16.9M in Same Qtr. Last Year; Outlook Reaffirmed

Financial news for DRNA dated on 2016-10-13: S-3 from Dicerna Pharma Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for DRNA dated on 2016-10-03: 15 Stocks That Rallied For Three Days On Increasing Volume, No News

Financial news for DRNA dated on 2016-09-26: Dicerna Prioritizes Resources to Advance GalXC Product Candidates, Clinical Development Discontinued For DCR-MYC In Oncology Indications

Financial news for DRNA dated on 2016-09-22: 10 Stocks With Three-Day Increasing Volume

Financial news for DRNA dated on 2016-09-21: 22 Stocks With Three-Day Increasing Volume

Financial news for DRNA dated on 2016-09-20: 30 Stocks With Three-Day Increasing Volume

Financial news for DRNA dated on 2016-08-04: Dicerna Reports Q2 EPS \$(0.75) vs. Est. \$(0.84)

Financial news for DRNA dated on 2016-07-05: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for DRNA dated on 2016-06-29: Dicerna Data Presentation Of GalXC To Occur At Investor Day Conf. Sees INDA Application In Late FY17

Financial news for DRNA dated on 2016-05-13: Dicerna Reports Dosing of Initial Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1

Financial news for DRNA dated on 2016-05-11: Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates

Financial news for DRNA dated on 2016-05-09: Dicerna Reports Q1 EPS \$(0.76) vs \$(0.86) Est.

Financial news for DRNA dated on 2016-04-18: Dicerna Announces Appointment of John "Jack" Green as CFO

Financial news for DRNA dated on 2016-04-18: Dicerna Names John "Jack" Green CFO

Financial news for DRNA dated on 2016-04-04: Chardan Capital Initiates Coverage on Dicerna Pharmaceuticals at Neutral, Announces \$5.00 PT

Financial news for DRNA dated on 2015-12-29: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for DRNA dated on 2015-12-21: Dicerna Initiates Dosing For First Healthy Volunteer Clinical Trial For Primary Hyperoxaulria Type 1 Treatment, Expects TO Start Phase 1 Trial In Patients By Early 2016

Financial news for DRNA dated on 2015-12-21: Dicerna Updates Progress on the Development of DCR-MYC for the Solid Tumor Treatment

Financial news for DRNA dated on 2015-12-15: Dicerna Pharmaceuticals Names John "Jack" Green Interim CFO

Financial news for DRNA dated on 2015-11-10: Dicerna Reports Q3 EPS \$(0.82) vs. Est. \$(0.84)

Financial news for DRNA dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for DRNA dated on 2015-09-08: Cowen & Company Initiates Coverage on Dicerna Pharmaceuticals at Outperform

Financial news for DRNA dated on 2015-09-02: Dicerna Pharmaceuticals Submits Investigational New Drug (IND) Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)

Financial news for DRNA dated on 2015-08-06: EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Financial news for DRNA dated on 2015-08-06: Dicerna Reports Q2 EPS \$(0.72) vs. Est. \$(0.78)

Financial news for DRNA dated on 2015-07-01: Dicerna Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for DRNA dated on 2015-06-11: Dicerna Issues Response To Alnylam Complaint

Financial news for DRNA dated on 2015-06-06: MaxLinear, PowerSecure, Alaska Air Lead After-Hours Movers To Close The Week

Financial news for DRNA dated on 2015-05-29: Benzinga's Top Initiations

Financial news for DRNA dated on 2015-05-29: Jefferies Initiates Dicerna Pharmaceuticals At Buy

Financial news for DRNA dated on 2015-05-29: Jefferies Initiates Coverage on Dicerna Pharmaceuticals at Buy, Lowers \$25.00 PT

Financial news for DRNA dated on 2015-05-21: Morning Market Losers

Financial news for DRNA dated on 2015-05-21: Benzinga's Top #PreMarket Losers

Financial news for DRNA dated on 2015-05-20: Dicerna Prices 2.75M Share Offering @\$17.75/Share

Financial news for DRNA dated on 2015-05-18: Dicerna Reports Follow-On Offering of 2.75M Shares

Financial news for DRNA dated on 2015-05-14: Dicerna Reports Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs)

Financial news for DRNA dated on 2015-05-11: Dicerna Pharma Reports Q1 Loss \$0.79 Vs Est Loss \$0.73

Financial news for DRNA dated on 2015-04-23: Dicerna Pharma Announces FDA Has Granted Orphan Drug Designation for DCR-PH1 for Treatment of PH1

Financial news for DRNA dated on 2015-04-23: FDA Grants Orphan Drug Designation for Dicerna's DCR-PH1

Financial news for DRNA dated on 2015-04-21: Biotech Investors: May 29th Could Be A Big Day

Financial news for DRNA dated on 2015-04-10: Dicerna Presents New b-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting

Financial news for DRNA dated on 2015-03-12: Dicerna Reports Q4 Adj. EPS \$(0.57) vs. Est. \$(0.57)

Financial news for DRNA dated on 2015-02-02: Dicerna Pharma Announces First Patient Dosing

Financial news for DRNA dated on 2015-01-12: Dicerna Receives US Patent Providing Broad Coverage of DsiRNA-EX RNAi Payloads

Financial news for DRNA dated on 2015-01-12: Dicerna Pharmaceuticals Presents Positive Preclinical Data On Its DsiRNA Therapeutics Targeting MYC and b-Catenin at AACR MYC

Financial news for DRNA dated on 2014-11-17: UPDATE: Dicerna Announces License Agreement With Tekmira

Financial news for DRNA dated on 2014-11-17: Dicerna Announces License Agreement With Tekmira

Financial news for DRNA dated on 2014-11-07: UPDATE: Stifel Reiterates On Dicerna Pharmaceuticals As DCR-MYC Is Progressing Nicely

Financial news for DRNA dated on 2014-11-07: Stifel Nicolaus Maintains Buy on Dicerna Pharmaceuticals, Lowers PT to \$21.00

Financial news for DRNA dated on 2014-11-06: Dicerna Pharmaceuticals Reports Q3 EPS of \$(0.54) vs \$(0.63) Est

Financial news for DRNA dated on 2014-11-06: Dicerna Pharmaceuticals Expects to Initiate Phase 1 Trial of DCR-PH1 in 2015

Financial news for DRNA dated on 2014-10-14: Dicerna Presents Preclinical Data for Investigational RNAi Therapeutic DCR-PH1 in Primary Hyperoxaluria Type 1 (PH1) at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society

Financial news for DRNA dated on 2014-08-21: Dicerna Announces Multiple Patents Covering Claims for Dicer Substrate siRNAs

Financial news for DRNA dated on 2014-06-30: Benzinga's Volume Movers

Financial news for DRNA dated on 2014-06-30: Morning Market Movers

Financial news for DRNA dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for DRNA dated on 2014-06-09: Top Healthcare Movers For June 9, 2014

Financial news for DRNA dated on 2014-05-14: Stifel Nicolaus Maintains Buy on Dicerna Pharmaceuticals, Lowers PT to \$44.00

Financial news for DRNA dated on 2014-05-13: Dicerna Pharma Reports Q1 Adj. Loss of \$0.56/Share

Financial news for DRNA dated on 2014-05-13: Dicerna Pharmaceuticals Reports Q1 EPS of \$(1.02) vs \$(0.52) Est

Financial news for DRNA dated on 2014-04-16: Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC

Financial news for DRNA dated on 2014-04-02: Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical Officer

Financial news for DRNA dated on 2014-04-02: Stocks Hitting 52-Week Lows

Financial news for DRNA dated on 2014-02-24: UPDATE: Stifel Initiates Coverage on Dicerna Pharmaceuticals on Riding the RNAi Wave

Financial news for DRNA dated on 2014-02-24: Benzinga's Top Initiations

Financial news for DRNA dated on 2014-02-24: Stifel Nicolaus Initiates Coverage on Dicerna Pharmaceuticals at Buy, Announces \$53.00 PT

Financial news for DRNA dated on 2014-02-24: Jefferies Initiates Coverage on Dicerna Pharmaceuticals at Buy, Announces \$48.00 PT

Financial news for DRNA dated on 2014-02-09: Financial Times Reports Large Number of US Biotech IPOs Could Indicate Bubble is Near

Financial news for DRNA dated on 2014-01-30: UPDATE: Dicerna Shares Rise as High as \$34.81 on IPO, Currently Trading Around \$30

Financial news for DRNA dated on 2014-01-30: Dicerna Pharmaceuticals Shares Resume After Circuit Breaker Halt

Financial news for DRNA dated on 2014-01-30: Dicerna Prices 6M Share IPO at \$15.00/Share

Financial news for DRNA dated on 2014-01-28: Dicerna Pharmaceuticals Raises IPO to 6M Shares from 5M